Type 2 Diabetes - Merck Announces FDA Acceptance Of New Drug Application For JANUVIA™, The Company''s Investigational Medicine

... Merck & Co., Inc. announced that the New Drug Application (NDA) for JANUVIA™* (sitagliptin phosphate) has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck expects FDA action on the NDA by mid-October. The Company also is moving forward as planned with filings in countries outside the United States... click link for more info. ...